Albuquerque, NM – According to filings with the U.S. Securities and Exchange Commission, Circular Genomics is raising $3,240,000.00 in new funding. Sources indicate as part of senior management President, Alexander Hafez played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Circular Genomics
Circular Genomics Inc is a biotechnology and genomics company using circular RNAs as novel and improved biomarkers for the diagnosis and better treatment of psychiatric and neurological diseases. Founded in 2021, using technology discovered at the University of New Mexico, we are developing the first RNA-based diagnostic assay to provide physicians with an optimal therapeutic course of action in treating major depressive disorder. With our innovative and insightful technology, Circular Genomics is leading the research and discovery of cutting-edge circular RNA-based diagnostics and therapeutics. Our incredible team is made of leading neuroscientists and psychiatrists working tirelessly to fill the need of reliable diagnostics in mental health care.

To learn more about Circular Genomics, visit http://www.circulargenomics.com/

Contact:
Alexander Hafez, President
505-357-0792
https://www.linkedin.com/in/ahafezk/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved